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Background—Some countries fortify flour with folic acid to prevent neural tube defects but
others do not, partly because of concerns about cancer risks. We aimed to assess the effects of
folic acid supplementation on site-specific cancer rates in the randomised trials.
Methods—Meta-analyses of data on each individual in all placebo-controlled trials of folic acid
for prevention of cardiovascular disease (10 trials, n=46,969) or colorectal adenoma (3 trials,
n=2652) that recorded cancer incidence and recruited >500 participants. All trials were evenly
randomised. Risk ratios (RRs) compare those allocated folic acid vs those allocated placebo,
giving cancer incidence rate ratios (among those still free of cancer) during, but not after the
scheduled treatment period.
Findings—During a weighted mean follow-up duration of 5.5 years, allocation to folic acid
quadrupled plasma folate, but had no statistically significant effect on overall cancer incidence
(1904 vs 1809 cancers, RR=1.06 [95%CI 0.99–1.13], p=0.10; trend with duration of treatment
p=0.46). There was no significant heterogeneity between the results of individual trials (p=0.23),
or between the cadiovascular prevention trials and the adenoma prevention trials (p=0.13).
Moreover, there was no significant effect of folic acid supplementation on the incidence of cancer
of the large intestine, prostate, lung, breast or any other specific site.
Interpretation—Folic acid supplementation does not substantially increase or decrease site-
specific cancer incidence during the first 5 years of treatment.
Funding—British Heart Foundation, Medical Research Council, Cancer Research UK, Food
Standards Agency.
Introduction
After epidemiological studies found that higher intakes of folate and plasma levels of folate
during pregnancy were inversely associated with neural tube defects,1–3 non-randomised4,5
and randomised intervention trials6,7 confirmed a protective effect, and folate is now
routinely recommended as a supplement before and during pregnancy.8 Furthermore,
population-wide folate fortification of flour for prevention of neural tube defects has been
mandatory since 1998 in North America, resulting in a two-fold increase in population
plasma folate levels.9,10 It is also mandatory in some other countries,9 including Chile,
Argentina, Brazil, South Africa and Australia;11–13 but in New Zealand and in Western
European countries it is not mandatory, partly due to concerns about possible adverse effects
on cancer incidence and prognosis.13–15
Epidemiological studies in adult populations have found inverse (ie, apparently protective)
associations of folate intake and of plasma folate levels with risk of cardiovascular
disease16,17 and colorectal cancer.18 To test whether there is any real protective effect
against cardiovascular disease, placebo-controlled trials of about 5 years of folic acid were
undertaken among a total of some 47,000 adults at high risk of vascular disease, and a
collaborative meta-analysis of individual patient data on cancer incidence from each these
trials was agreed prospectively in 2004, before any results emerged.19,20 These trials did not
suggest any protective effect of folic acid supplementation against cardiovascular disease or
against mortality from any cause during the scheduled trial treatment period.20
To test whether there is any real protective effect against colorectal adenomas, another 3
such trials were undertaken among a total of some 3000 patients. One of these, the Aspirin
and Folic Acid Polyp Prevention Study (AFPPS), reported in 2007 unexpected increases in
advanced colorectal adenomas and prostate cancer after 7 years of treatment with folic
acid.21 Also in 2007, it was suggested that transient increases in colorectal cancer incidence
in the United States (US) and Canada during 1996–98 might have been due to the 1996–98
introduction of folic acid fortification in North America.22 Taken together, these reports
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(and awareness that anti-folate drugs such as methotrexate are used for the treatment of
certain cancers) prompted regulatory concerns about possible risks of cancer associated with
folic acid supplements and folic acid fortification. Animal models had previously suggested
the possibility that high intakes of folate could suppress the development of early lesions in
normal tissue, but enhance the growth of established neoplasms.23
To see whether, in aggregate, the randomised trials of folic acid show an increase or
decrease in cancer risk over a period of just a few years, we present collaborative meta-
analyses of site-specific cancer incidence during the scheduled treatment period among a
total of 50,000 individuals from all available large cardiovascular and adenoma trials. We do
not address the question of whether any effects on cancer incidence will emerge among the
participants some years or decades after the trials ended.
Methods
Trial eligibility
Trials were identified by electronic searches using PUBMED with search terms for
“randomized trials”, ”folic acid”, “B-vitamins” or “homocysteine-lowering treatment” and
by scanning reference lists of trial reports: webappendix p2. Trials were eligible for
inclusion if (i) at least one randomized comparison was folic acid vs placebo with scheduled
treatment duration at least one year (irrespective of whether any other treatment was tested
factorially); (ii) there were 500 or more participants; and (iii) data on cancer incidence had
been recorded. Unpublished trials were sought through electronic searches and discussions
with other experts in the field, but none was found. Individual participant datasets were
obtained for 49 621 participants in 13 trials completed by the end of 2010: webappendix
p7.21,24–35 Information on cancer incidence was not recorded in two other trials involving a
total of 5992 participants.36,37 (Inclusion of the few cancer deaths recorded in such trials
would not materially alter the present meta-analyses of cancer incidence in all other trials.)
The protocol for trial identification, analysis and involvement of trialists was agreed
following discussion with all collaborators before any results emerged, and published
elsewhere.19,20
Baseline and follow-up data
For each participant, information was sought on characteristics recorded prior to
randomization, allocated treatment, and the type and date (or time from randomization) of
any cancer incidence or mortality during the scheduled treatment period. Information on
hospitalizations and cancer incidence was collected in each trial at 3 to 6 month intervals
during the scheduled treatment period. In addition to self-reported cancer, additional
information on cancer incidence was, where possible, obtained from national cancer
registries.26–28, 33 In one trial,29 the site of cancer onset was not recorded in the primary
database, so we searched all relevant databases of adverse events to identify incident
cancers. The other trials had all sought verification of incident cancers from hospital
electronic records or by writing to hospital or family physicians, and in them sites of cancer
onset were available for more than 92% of cases.
Analyses of the individual participant data were checked for consistency with any published
reports and with the trialists to help ensure that the data were incorporated correctly into the
meta-analysis. Investigators were asked to confirm summary data for each treatment group
on the number of randomized patients, on plasma levels of folate and homocysteine before
and after starting treatment, and on numbers who developed each of the pre-defined
outcomes.
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The main outcome was incident cancer, defined as the first occurrence after randomization
but during the scheduled treatment period of any non-fatal cancer (except non-melanoma
skin cancer) or fatal cancer. Where cancer was diagnosed only at death and no other
information was available, the date of diagnosis was taken as the date of death. Where
cancer site was available only for mortality, the data were used for analyses of incidence as
well as mortality. Cancers were subdivided into the 18 most common types, based on the
International Classification of Disease (ICD-10), with the aggregate of all other types as a
19th category and missing ICD codes as a 20th. Having individual participant data from each
trial facilitated uniform categorization of cancer types (and permitted analyses of treatment
effects in pre-specified subgroups).
Statistical analyses
Comparisons of cancer rates by allocated treatment were based on intention-to-treat analyses
of first events during the scheduled treatment period. The logrank observed minus expected
(o-e) statistics from each trial and their variances (v) were separately summed to produce,
respectively, a grand total observed minus expected statistic (G) and its variance (V).38 The
one-step estimate of the log of the event rate ratio is then G/V with variance 1/V (and 95%
CI G/V ± 1.96/√V). For n trials, a chi-squared statistic for heterogeneity with n−1 degrees of
freedom (χ2n−1) is S-G2/V, where S is the sum over all trials of (o-e)2/v.
The effects on cancer incidence were assessed in pre-defined subgroups of year of follow-up
(first 3 years or later), age, sex, plasma folate, plasma homocysteine, and whether or not
there was nationwide folic acid fortification. Heterogeneity of the rate ratios (RR) among
these subgroups was investigated by a global chi-squared test to reduce the chance of
misinterpreting any false positive results arising from multiple comparisons.39 99% CIs
were used for individual trials or subgroups (again to avoid misinterpreting false positive
results), but 95% CIs were used for the overall findings. To correct for multiple
comparisons, p-values for particular types of cancer were multiplied by the number of types
investigated (to a maximum corrected p-value of 1.0).40,41
To help re-assess the hypotheses of increased risk of colorectal adenoma and prostate cancer
raised by AFPPS,21 the present meta-analyses assessed the effects of folic acid on colorectal
and prostate cancer with and without exclusion of the AFPPS trial.40,41 The provision of (o-
e) for each trial facilitates sensitivity analyses that exclude or include particular trials.
Folate reduces homocysteine, and the mean reduction in all trials was the weighted mean of
study-specific percent homocysteine reductions, with weights proportional to the variances
of the logrank statistics for overall cancer incidence. Statistical Analysis System (SAS)
version 9.2 was used.
Role of the funding sources
The funders of the individual trials had no role in study design, data collection, data
analysis, data interpretation, or writing or submission of the report. The CTSU authors had
full access to all the data and analyses and accept responsibility for this report. Final
analyses and a draft report were circulated to all authors, revised and re-circulated. All
authors are responsible for the decision to submit for publication.
Results
Individual participant data were obtained from all 13 trials of at least 500 participants and
one year of scheduled treatment that had recorded cancer incidence, involving in total
49,621 participants (2652 from 3 trials in patients with a prior colorectal adenoma and
46,969 from 10 trials in people with or at high risk of cardiovascular disease: Table 1). Two-
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thirds of the participants were men and the mean age at entry was 64 (SD 10) years:
webappendix p7. The daily doses of folic acid ranged from 0.5 to 5 mg, except in one trial of
40 mg daily.25 All trials compared the effects of folic acid versus placebo, except one trial29
that compared analyses of 2.5 mg versus 0.02 mg (only 5% of the recommended dietary
intake; approximately equivalent to placebo). Treatment duration varied from 2.0 to 7.7
years, with weighted average 5.5 years.
Allocation to folic acid was associated with quadrupling median plasma folate levels (57.3
vs 13.5 nmol/L) and with reduction by a quarter in plasma homocysteine levels (9.3 vs 12.3
μmol/L): webappendix p6. As expected, effects on homocysteine levels were greater in non-
fortified than in fortified populations (27% and 20% reductions, respectively).20
Information was available on 3713 incident cancers during the scheduled treatment period.
Allocation to folic acid treatment did not have any statistically significant effect on overall
cancer incidence, with 1904 (7.7%) first events in 24,799 participants allocated folic acid
versus 1809 (7.3%) in 24,822 allocated control (RR 1.06; 95% CI 0.99–1.13, p=0.10: Figure
1). There was no significant heterogeneity between the results of individual trials
(χ212=15.3; p=0.23), or between the adenoma trials (96 vs 72 cancers, RR 1.33; 95% CI
0.98–1.80) and vascular trials (1808 vs 1737 cancers, 1.04; 95% CI 0.98–1.11) (χ21 = 2.2;
p=0.13).
Importantly, there was no evidence of an increasing effect of folic acid with increasing
duration of treatment (Figure 2), although only 3 of the trials lasted more than 5
years.21,31,33 Nor were there any significant differences by sex, age, pre-treatment blood
levels of folate, pre-treatment blood levels of homocysteine, folic acid fortification in the
population, folic acid dose or percent homocysteine reduction: webappendix pp3–4. Even in
the trial of 40 mg/day of folic acid there was no apparent increase in overall cancer
incidence (65 vs 72 cancers, RR=0.94; 99% CI 0.61–1.47).25
The 3713 cancers were classified into 18 main types. There was no statistically significant
effect of folic acid allocation on the incidence of colorectal cancer (221 vs 208; RR 1.07;
99%CI 0.83–1.37), lung cancer (272 vs 253; 1.08, 0.86–1.35), breast cancer (140 vs 157;
0.89, 0.66–1.20), prostate cancer (351 vs 305; 1.15, 0.94–1.41), the less common types, or
cancer of an unknown type, either overall or by treatment duration (Figure 3, Table 2,
webappendix p7).
Although there were conventionally significant protective effects against oesophagus cancer
during the first 3 years (7 vs 21) but not later (16 vs 11), and against breast cancer later (61
vs 92) but not during the first 3 years (79 vs 65), these unanticipated period-specific
protective effects ceased to be significant when corrected for multiple comparisons. For
adverse effects, however, even before any such corrections there were no conventionally
significant findings on any type of cancer in either time period.
Results for colorectal and prostate cancer are presented separately for each individual trial
(webappendix pp8–9), and the analyses were repeated after exclusion of the AFPPS trial,21
which had reported a statistically significant excess risk of colorectal adenomas and prostate
cancer. Overall, the remaining trials did not support a significant adverse effect on colorectal
cancer (1.08; 95%CI: 0.89–1.30; heterogeneity [AFPPS versus the other trials] χ21=0.28,
p=0.6) or prostate cancer (1.11; 95%CI: 0.95–1.30; heterogeneity [AFPPS versus the other
trials] χ21=4.46, p=0.03). The provision of (o-e) for each trial (webappendix pp8–10)
facilitates additional sensitivity analyses that exclude particular trials.
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Both the hopes for cancer prevention and the concerns about rapidly increased cancer risk
from folic acid supplementation are not confirmed by this meta-analysis of the large folic
acid trials. Although the point estimate for overall cancer incidence was slightly increased,
this apparent increase was compatible with a chance effect, and there was no apparent
increase in risk with increasing duration of treatment or dose of folic acid. Taking all studies
together, allocation to folic acid for an average duration of 5 years had no significant short-
term effect on overall or site-specific cancer incidence during the trials. In particular,
supplementation had no significant effect on the incidence of cancers of the large intestine
(despite the epidemiological evidence of protection),18 prostate, lung, breast or any other
specific site, even in the period more than 3 years after randomization, although the power to
detect differences for cancer at particular sites at varying intervals of follow-up is limited.
The results of the present meta-analysis, involving 49,621 participants, are unlikely to be
biased by the lack of availability of data on cancer incidence from two small trials of 1882
and 4110 participants that were treated with folic acid for 2 and 4 years, respectively.36,37
A previous meta-analysis using summary data from a sub-set of these trials suggested a
marginally significant excess of prostate cancer.42 The present meta-analysis, however,
which used individual participant data in a time-to-event analysis from all large trials, found
no significant excess of prostate cancer or of any other type of cancer. Thus, any excess risk
of prostate cancer from folic acid supplementation was most likely exaggerated by the play
of chance in the AFPPS results.43 Appropriate interpretation of such findings requires
avoidance of unduly selective emphasis on particular trials by analyzing all trials, and by
hypothesis testing after excluding the results of the hypothesis-generating trial.40,41 For, an
apparent excess or shortfall of some types of cancer in individual trials can be expected by
chance alone when many different types of cancer are analyzed separately.
Although many of the trials used combinations of B-vitamins (vitamin B12 and vitamin B6
in addition to folic acid), it is unlikely that this would have concealed any effects of folic
acid alone on cancer rates. The median daily dose of folic acid in the trials was 2.0 mg,
which is much greater than in most widely used vitamin supplements (0.1 – 0.8 mg) and an
order of magnitude greater than the dose of 0.1 – 0.2 mg typically delivered by flour
fortification programs.8
Despite the low doses provided by fortification, it had been suggested that transient
increases in colorectal cancer incidence in the US and Canada in 1996–98 (during the 3-year
period in which nationwide introduction of folate fortification was being established) might
have been due to fortification.22 Although the observed increases in colorectal cancer
incidence during 1996–98 are unexplained, they occurred too soon to be plausibly ascribable
to the introduction of folate fortification during 1996–98 and did not persist after 1998.
Moreover, national trends in mortality from colorectal cancer in the US at ages 35–69 years
(which are less likely to be influenced by artefactual trends in cancer detection or
registration rates) show no evidence of any new hazard after the introduction of fortification:
Figure 4. Likewise, examination of US mortality rates at ages 35–69 years from the other
main types of cancer (data not shown) provides no good evidence of any hazard following
fortification.
Although our meta-analyses included all large trials of folic acid, the power to exclude
beneficial or adverse effects on cancer at individual sites was limited by the number of
cancers and the relatively short duration of follow-up in these trials. While the present meta-
analyses addresses the effects of high doses of folic acid on cancer during the scheduled trial
treatment period, they do not address the question of whether any beneficial or harmful
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effects on cancer incidence will eventually emerge among the participants many years after
the trials ended. Follow-up for decades after the trials ended may be feasible, especially in
populations with automated record linkage to cancer registries and causes of death, but again
it will be important not to place unduly data-dependent emphasis on the results for specific
types of cancer in individual trials after particular follow-up durations.
Nevertheless, the human evidence about folic acid and cancer that has impeded folic acid
fortification in the UK and some other countries involved apparent increases in incidence of
colorectal and prostate cancer within just the first few years of starting treatment which, if
real, should have been detectable during the trials. The present meta-analyses (which include
the hypothesis-generating trial) address this issue directly, showing that in aggregate the
trials provide no statistically significant evidence of short-term effects of folic acid
supplementatation on overall cancer incidence, or on the incidence of any particular type of
cancer. The present meta-analysis rules out moderate increases in overall cancer incidence
from folic acid supplementation during the trials. Large increases in common cancer types
are similarly unlikely. Since fortification involves folic acid doses an order of magnitude
lower, its effects on cancer risk are likely to be even smaller.
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Regulatory concerns about possible adverse effects of folic acid on cancer have delayed
the introduction of folic acid fortification of flour for the prevention of neural tube
defects in the United Kingdom and many other countries. The human evidence
underlying these concerns involved apparent increases in cancer incidence within only a
few years of starting treatment.
Now
Evidence from some trials that folic acid substantially increased site-specific cancer
incidence within just a few years in certain trials is not supported by the other trials, or by
the overall results from all trials.
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Figure 1. Effects of folic acid allocation on overall first cancer incidence
The black squares denote the rate ratios (RRs) and horizontal lines the 99% confidence
intervals (CIs). Each square has area inversely proportional to the variance of the log of the
rate ratio. The diamonds represent the summary estimates and their corresponding 95% CIs.
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Figure 2. Effects of folic acid on cancer incidence in all available trials, by year of follow-up
The black squares denote the rate ratios (RRs) and horizontal lines the 99% confidence
intervals (CIs). Each square has area inversely proportional to the variance of the log of the
rate ratio. The diamonds represent the summary estimates and their corresponding 95% CIs.
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Figure 3. Effects of folic acid on first cancer incidence, by type and duration of treatment
The black squares denote the rate ratios (RRs) and horizontal lines the 99% confidence
intervals (CIs). Each square has area inversely proportional to the variance of the log of the
rate ratio. The diamonds represent the summary estimates and their corresponding 95% CIs.
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Figure 4. Colorectal cancer mortality trends, 1950–2008, in the United States at ages 35–69
Male (upper line) and female annual mortality rates: rates at ages 35–69 are calculated as the
mean of the annual rates in the seven component 5-year age groups. Source: WHO mortality
database and UN population tables. Mortality rates at ages 35–69 years were standardised
for age by averaging the seven component 5-year age groups. If the annual rate per 100,000,
standardised in this way, is R, then the 35-year death rate from colorectal cancer, ignoring
competing risks, is 1−exp(−35R/100,000).
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